男性BRCA1和BRCA2基因突变携带者：一项关于参与前列腺癌预防诊所患者医学特征的试点研究。
Male BRCA1 and BRCA2 mutation carriers: a pilot study investigating medical characteristics of patients participating in a prostate cancer prevention clinic.
作者信息
Horsburgh Sheri, Matthew Andrew, Bristow Robert, Trachtenberg John
机构信息
Department of Surgical Oncology, University Health Network, Toronto, Ontario, Canada.
出版信息
Prostate. 2005 Oct 1;65(2):124-9. doi: 10.1002/pros.20278.
BACKGROUND
Male BRCA1 and BRCA2 mutation carriers are at an increased risk to develop prostate cancer and are subject to screening protocols for high-risk men. The utility of targeted screening, and the clinical and pathological features associated with prostate cancer, have received little attention in this population.
METHODS
We report on the clinical screening and pathological characteristics of a group of 19 men with BRCA1 or BRCA2 mutation, as compared to an age-matched group of men with a family history of prostate cancer.
RESULTS
Mutation carriers were significantly more likely to have an elevated PSA at first visit (P = 0.03). Prostate cancer was twice as likely to be diagnosed in mutation carriers although this difference was not statistically significant (P = 0.55).
CONCLUSIONS
Prostate cancer surveillance of BRCA1 and BRCA2 mutation carriers is warranted. Further research on larger cohorts is needed to evaluate whether unique pathological prostate cancer characteristics exist in these men.
背景
携带BRCA1和BRCA2基因突变的男性患前列腺癌的风险增加，需接受针对高危男性的筛查方案。在这一人群中，靶向筛查的效用以及与前列腺癌相关的临床和病理特征很少受到关注。
方法
我们报告了一组19名携带BRCA1或BRCA2基因突变男性的临床筛查和病理特征，并与一组年龄匹配的有前列腺癌家族史的男性进行了比较。
结果
突变携带者首次就诊时PSA升高的可能性显著更高（P = 0.03）。突变携带者被诊断出前列腺癌的可能性是其他人的两倍，尽管这种差异无统计学意义（P = 0.55）。
结论
对携带BRCA1和BRCA2基因突变者进行前列腺癌监测是必要的。需要对更大的队列进行进一步研究，以评估这些男性是否存在独特的前列腺癌病理特征。
Zotero 插件